Recent News

• 05.13.2025 - Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
• 04.28.2025 - Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
• 03.27.2025 - Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
• 02.25.2025 - UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
• 01.10.2025 - Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Recent Filings

• 05.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.28.2025 - EX-99.1 EX-99.1
• 04.28.2025 - DEF 14A Other definitive proxy statements
• 04.28.2025 - 8-K Current report
• 03.28.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - 8-K Current report